Literature DB >> 29588246

Drug survival of apremilast in patients treated for psoriasis in a real-world setting.

Erica B Lee1, Mina Amin2, Jashin J Wu3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29588246     DOI： 10.1016/j.jaad.2018.03.028

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  2 in total

1.  Apremilast Survival and Reasons for Discontinuation in Psoriasis: Five-Year Experience From a Greek Tertiary Care Centre.

Authors:  Elena Sotiriou; Aikaterini Tsentemeidou; Nikolaos Sideris; Aimilios Lallas; Nikolaos Kougkas; Dimitrios Ioannides; Efstratios Vakirlis
Journal:  Dermatol Pract Concept       Date:  2022-01-01

Review 2.  Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature.

Authors:  Deepak M W Balak; Sascha Gerdes; Aurora Parodi; Laura Salgado-Boquete
Journal:  Dermatol Ther (Heidelb)       Date:  2020-06-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.